Page URL: https://www.bionews.org.uk/page_93739

The House of Lords inquiry into regenerative medicine: mapping the UK route for the commercialisation of cell therapies

20 August 2012
By Dr Emily Culme-Seymour
Director of the London Regenerative Medicine Network (LRMN)
Appeared in BioNews 669

The UK House of Lords Science and Technology Select Committee (1) has launched an inquiry into cell therapy and regenerative medicine to take place this autumn. The focus of this inquiry will be whether the UK is sufficiently well placed for the successful translation and commercialisation of research into patient-ready treatments. The inquiry will also ask whether the UK can integrate its efforts into facilitating this process.

The Select Committee analyses Government policy on a wide range of topics relating to science and technology, including a variety of public policy areas. The Committee currently has 14 members from across the political spectrum and is chaired by Lord Krebs, the acclaimed zoologist.

This is not the first time that the House of Lords has examined issues in this sector. In 2002, a Select Committee on Stem Cell Research published a notable report on matters relating to stem cell research and human cloning. The latest inquiry, however, is broader and more focused on translation and more specifically commercialisation than research. It also reaches beyond stem cells to the wider cell therapy and regenerative medicine sectors.

'Regenerative medicine' is the replacement or regeneration of human cells, tissues or organs to restore or establish normal function (2). It includes cell therapies, gene therapies, tissue engineering and biomedical engineering techniques.

A large amount of world-class research and development in regenerative medicine takes place in the UK, including work on cell therapies, on small molecules to trigger in vivo responses to disease, and early developmental-stage research. Internationally, there is a wealth of regenerative medicine and cell therapy developments underway. This fierce pace of development has advanced the field but also revealed new challenges including how best to commercialise the technology. In this context, the focus of the inquiry on regenerative medicine, and how best to facilitate UK translation and commercialisation, is timely.

Significant developments in the UK over the past few years have improved the funding environment for those working in this sector. The recent establishment of the Technology Strategy Board (TSB)-backed Cell Therapy Catapult at Guy's Hospital in London, and the announcement of a £25 million cross-research council UK Regenerative Medicine Platform fund are two prime examples. In addition, the £180 million TSB/Medical Research Council Biomedical Catalyst Fund launched earlier this year and the £650m interdisciplinary medical research initiative (the Francis Crick Institute) are both likely to include regenerative medicine-focused translation projects within their remit.

However, the later stages of the process from lab bench to patient bedside remain particularly important. Gaining regulatory approval, negotiating reimbursement with healthcare providers, improving access to patients, and establishing long-term clinical uptake all pose challenges.

Regenerative medicines face unique issues with regards to many of these steps. For example, clinical trials  that require large numbers of identical batches of cells to be used in treating patients present challenges in relation to proven reproducible manufacturing. In addition, the regulatory approval for a clinical trial will often be such that it allows treatment of patients only in the late phase of their condition. This often results in the trial therapy being tested on the target condition but with associated complex multisystem pathology and thus little real opportunity to demonstrate significant patient benefit.

At the same time, therapies need to remain cost-effective to garner recommendation from the National Institute for Health and Clinical Excellence (NICE). Making such highly-personalised medicines, such as autologous cell therapies, available on the NHS, is essential for their reaching large numbers of patients. Then, of course, their price has to be sufficient to ensure commercial viability.

The Select Committee inquiry presents an excellent opportunity for those involved with and interested in the sector to express their views and help shape the future of policy and regulation in this field. The Committee has published a call for evidence inviting written submissions by 20 September 2012. The call covers topics including the research base, the application of science, barriers to translation and commercialisation, and international comparisons.

With the UK being a world leader on cell therapy development, stem cell research and personalised medicine, we now have the opportunity to identify and resolve the bottlenecks in the translation and commercialisation process, and move efficiently towards economic growth from the sector. It is to be hoped that there will be broad and enthusiastic support for this Select Committee as it will be the UK's last chance to become a global leader in the commercialisation of cell therapies.

SOURCES & REFERENCES
1) Science and Technology Committee (Lords)
www.parliament.uk |  22 October 2020
2) Cell therapy and regenerative medicine glossary
Regenerative Medicine 7(3 Suppl.), S1–S124 (2012) |  1 April 2012
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
14 October 2013 - by Julian Hitchcock 
Since the Coalition came to power, we've grown used to its backing of science and technology. So, when the Government published its response to the House of Lords Science and Technology Committee Inquiry into Regenerative Medicine last week, there was barely a murmur from the sector as recommendation after recommendation was endorsed and translated into action....
8 July 2013 - by Antony Starza-Allen 
A House of Lords committee has said the UK is currently underprepared for developments in regenerative medicine and called on the Government to act to ensure the UK maintains its leading role in the field....
4 February 2013 - by Dr Rachael Panizzo 
Shortly after being awarded the 2012 Nobel prize in physiology or medicine, Professor Sir John Gurdon was interviewed for the BBC Radio 4 programme 'The Life Scientific'...
17 September 2012 - by Dr Linda Wijlaars 
It is not often that you get the chance attend a seminar organised by an institution that is still under construction. Due to open in 2015, the building that will house the Francis Crick Institute currently comprises a rudimentary basement and ground floor, a handful of towering cranes and a swanky visitor centre...
18 February 2012 - by Rachel Lloyd 
The principal purpose of Professor Emily Jackson's book, Law and the Regulation of Medicines, is to outline medicine's journey through UK regulation. Jackson seeks to show that those responsible for the content of the regulatory regime, and the way in which it is administered, play a crucial role in shaping the development, supply and marketing of medicines....
25 July 2011 - by Julianna Photopoulos 
Funding from private, non-profit, and public sectors will be needed for the UK to maintain its 'world leading' role in regenerative medicine, according to a recent Government strategy report....
16 November 2009 - by Nisha Satkunarajah 
The California Institute for Regenerative Medicine (CIRM) has awarded fourteen teams a total of $230 million for the advancement of stem cell therapy. The CIRM was created as a measure by the Californian State to fund work on human embryonic stem (ES) cells.Californian voters approved the 10-year, $3 billion effort in 2004 largely to get around restrictions on ES cell research imposed by the administration of President George W Bush. This year, President Obama's administration relaxed thes...
9 July 2009 - by MacKenna Roberts 
When giving evidence to the Lords' inquiry into genomic medicine, Health Minister Dawn Primarolo estimated that the vast potential benefits of genomic medicine will not largely be seen by patients for at least a decade. The House of Lords Science and Technology Committee respectfully but conclusively disagrees in its report on Genomic Medicine, published 7 July 2009. Lord Patel who chaired the inquiry surmised; 'Genomic medicine will clearly have a huge impact on health provision and the NHS
12 May 2009 - by Paul Martin and Emma Rowley 
Regenerative medicine, including stem cells and tissue engineering, holds great hope for the future in terms of addressing the unmet health needs of patients. In particular, much attention has been paid to the potential of novel stem cell based therapies following a series of major scientific breakthroughs and media reports...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.